The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells

By sjmartinez • February 19, 2024

Lewis MI, Shapiro S, Oudiz RJ, Nakamura M, Geft D, Matusov Y, Hage A, Tapson VF, Henry TD, Azizad P, Saggar R, Mirocha J, Karpov OA, Van Eyk JE, Marbán E. The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells. EBioMedicine. 2024 Feb;100:104900. doi: 10.1016/j.ebiom.2023.104900. Epub 2023 Dec 12. PMID: 38092579.

Tags: Cardiology/Epi, Cedars Sinai DoM, Harbor UCLA, Progenitor cell therapy, Publications, pulmonary arterial hypertension, Pulmonary, Critical Care & Sleep Medicine, Regenerative medicine, right ventricle, Short- and long-term safety, Veterans Administration

Related Posts

Ethnic differences in coronary plaque burden and characteristics: A matched CCTA cohort study of South Asians and non-Hispanic Whites

Manubolu VS, Kinninger A, Lakshmanan S, Dahal S, Ichikawa K, Verghese D, Alalawi L, Aldana J, Susarla S, Seok HJ, Dailing C, Roy SK, Rohatgi[...]

Biomimetic, Suturable, and Extensible Electrospun Scaffolds for Lower Urinary Tract Surgical Reconstruction

Sturm RM, Huo Y, Yiu F, Gu Y, Afshari R, Zhong Z, Jimenez R, Jung R, Cabuan A, Shukla K, Harrison K, Su J, Aninwene[...]

Machine learning-assisted point-of-care diagnostics for cardiovascular healthcare

Wang K, Tan B, Wang X, Qiu S, Zhang Q, Wang S, Yen YT, Jing N, Liu C, Chen X, Liu S, Yu Y. Machine[...]